SPONSOR
Alkermes, Inc.
Total Trials
3
Recruiting
3
Phases
Phase 2, Phase 3
Conditions studied: Attention Deficit Disorder With Hyperactivity (ADHD)Idiopathic HypersomniaNarcolepsy Type 1
Alkermes, Inc. is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Attention Deficit Disorder With Hyperactivity (ADHD), Idiopathic Hypersomnia, Narcolepsy Type 1.
The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Alkermes, Inc.
How many clinical trials has Alkermes, Inc. sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Alkermes, Inc., of which 3 are actively recruiting participants. These trials cover conditions including Attention Deficit Disorder With Hyperactivity (ADHD), Idiopathic Hypersomnia, Narcolepsy Type 1. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Alkermes, Inc. research focus on?
Alkermes, Inc. clinical trials span Attention Deficit Disorder With Hyperactivity (ADHD), Idiopathic Hypersomnia, Narcolepsy Type 1. The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Alkermes, Inc. clinical trial?
To participate in a Alkermes, Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Alkermes, Inc. trials with current recruitment status updated daily.
Clinical Trials by Alkermes, Inc.
NCT07755410 Phase 2
Recruiting
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
Attention Deficit Disorder With Hyperactivity (ADHD)
NCT06843590 Phase 2
Recruiting
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
Idiopathic Hypersomnia
NCT07455383 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Narcolepsy Type 1
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology